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Abstract
Protein phosphorylation regulates a wide variety of cellular processes. Thus, we hypothesize that 
single nucleotide polymorphisms (SNPs) that may modulate protein phosphorylation could affect 
osteoporosis risk. Based on a previous conventional genome-wide association (GWA) study, we 
conducted a three-stage meta-analysis targeting phosphorylation-related SNPs (phosSNPs) for 
femoral neck (FN)-, total hip (HIP)-, and Lumbar Spine (LS)-BMD phenotypes. In stage 1, 9,593 
phosSNPs were meta-analyzed in 11,140 individuals of various ancestries. Genome-wide 
significance (GWS) and suggestive significance were defined by α = 5.21×10−6 (0.05/9,593) and 
1.00×10−4, respectively. In stage 2, 9 stage 1-discovered phosSNPs (based on α = 1.00×10−4) 
were in silico meta-analyzed in Dutch, Korean, and Australian cohorts. In stage 3, four phosSNPs 
that replicated in stage 2 (based on α = 5.56×10−3, 0.05/9) were de novo genotyped in two 
independent cohorts. IDUA rs3755955 and rs6831280, and WNT16 rs2707466 were associated 
with BMD phenotypes in each respective stage, and in 3 stages combined, achieving GWS for 
both FN-BMD (P-value = 8.36×10−10, 5.26×10−10, and 3.01×10−10, respectively) and HIP-BMD 
(P-value = 3.26×10−6, 1.97×10−6, and 1.63×10−12, respectively). Although in vitro studies 
demonstrated no differences in expressions of wild-type and mutant forms of IDUA and WNT16B 
proteins, in silico analysis predicts that WNT16 rs2707466 directly abolishes a phosphorylation 
site, which could cause a deleterious effect on WNT16 protein, and that IDUA phosSNPs 
rs3755955 and rs6831280 could exert indirect effects on nearby phosphorylation sites. Further 
studies will be required to determine the detailed and specific molecular effects of these BMD-
associated non-synonymous variants.
Keywords
osteoporosis; human association studies; single nucleotide polymorphism; meta-analysis; Wnt/
Beta-catenin/LRPs
INTRODUCTION
Osteoporosis, a complex disease characterized by reduced bone mass, results in 
microarchitectural deterioration of bone tissue, and increased bone fragility and 
susceptibility to fracture.(1) It has been estimated that the prevalence of osteoporosis in the 
United States will increase to >14 million people in 2020,(2) and by 2025 it is projected that 
there will be >3 million fractures/year in the U.S., costing $25.3 billion annually.(3) A 
diagnosis of osteoporosis for both males and females is attained when bone mineral density 
(BMD) is 2.5 standard deviations or more below the young adult mean.(4) BMD, a highly 
heritable polygenic trait, is the best predictor for skeletal fragility.(5)
Protein phosphorylation represents the most widespread post-translational modification 
(PTM), which plays a critical role in essential cellular processes, e.g., metabolism, cell 
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signaling, differentiation, and membrane transportation.(6) Large-scale phosphoproteomics 
studies suggest that more than half of all eukaryotic proteins are phosphorylated.(7) The 
most common phosphorylation sites in eukaryotes are serine (S), threonine (T), and tyrosine 
(Y) residues,(8) which are catalyzed by S/T-specific, Y-specific, and dual-specificity protein 
kinases.(9) Single nucleotide polymorphisms (SNPs) constitute almost 90% of genetic 
variations in the human genome.(10) Non-synonymous SNPs (nsSNPs), defined as SNPs 
resulting in amino acid changes that include either missense or nonsense mutations,(11) 
represent 60% of known disease-causing mutations.(12) Of them, those that create/alter/
abolish phosphorylation sites, called phosphorylation-related SNPs (phosSNPs), have been 
recognized as functional variants for a spectrum of human diseases, e.g., lung cancer 
(CSF1R rs10079250),(13) prostate cancer (TP53 rs1042522),(13,14) long QT syndrome 
(KCNH2 rs1805123),(15,16) systemic lupus erythematosus (VEGR2 rs2305948),(17) and 
tuberculosis (TLR2 rs5743708).(18,19) Each phosphorylation site consists of an acceptor 
residue surrounded by an evolutionarily conserved motif consisting of 7–12 amino acid 
residues on either flanking region. Based on the hypothesis that a sequence motif 
surrounding an acceptor residue represents a main determinant of protein kinase specificity, 
phosphorylation sites can be predicted in silico, and nsSNPs affecting such sites can be 
identified. From 91,797 nsSNPs of NCBI dbSNP Build 130, by applying the Group-based 
Phosphorylation Scoring (GPS) 2.0 program (a kinase-specific phosphorylation site 
predictor)(20), Ren et al. (2010)(21) identified 64,035 phosSNPs residing in 17,614 human 
proteins, which were categorized into five distinct types: I, II, III, IV and V based on the 
different effects they exert on phosphorylation sites.
Among at least 60 loci identified by > 40 previous genome-wide association (GWA) studies 
and meta-analyses of these studies for osteoporosis, WNT16 locus has been found to be an 
important genetic determinant of osteoporosis risk.(22) The human WNT16 gene spans ~16 
kb from initiation to termination codons, encoding two protein isoforms — WNT16A (40.5 
kD) and WNT16B (40.7 kD).(23) As depicted in Supplementary Figure S1, these two 
WNT16 isoforms have different first exons (i.e., 1a and 1b, respectively), independently 
controlled by two alternative promoters P1 and P2, respectively.(24) Expression of the 
WNT16A isoform has been shown to be restricted to the pancreas in humans, whereas 
WNT16B is expressed in multiple organs.(24) Compared to WNT16A, the role of WNT16B 
as a key regulator of osteoclastogenesis has been more extensively characterized.(25)
Meta-analyses of GWA studies have significant potentials for detecting subtle genetic 
effects.(26) However, because conventional GWA studies often include a large number of 
variants of unknown functional effects, the significance threshold attained by Bonferroni 
correction becomes overly conservative, producing a high rate of type II error (i.e., β). 
PhosSNPs are more likely disruptive to protein function than other protein-coding missense 
mutations.(27) However, such potentially causal missense mutations could be missed by 
conventional GWA approaches, due to very strict control for type I error (i.e., α). Power to 
detect disease-causing variants can thus be increased by focusing exclusively on SNPs with 
higher prior probabilities of functional effects, either as in a whole-exome sequencing(28) 
approach targeting solely exonic SNPs, or as we apply here, targeting exclusively potentially 
functional phosSNPs. However, such a functional candidate genomic region approach(29) 
could be susceptible to a higher rate of false positive results.(30) Therefore, to guard against 
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an inflated α, we employed a three-stage approach, such that those phosSNPs attaining 
genome-wide significance (GWS) in stage 1 (i.e., GWA discovery) are required to be 
replicated in independent cohorts of stages 2 and 3, respectively, based on their 
corresponding Bonferroni-corrected α thresholds.
MATERIALS AND METHODS
A detailed description of study participants, phenotype measurement and modeling, DNA 
genotyping, quality control (QC), and genotype imputation, association tests, meta-analysis 
methods, and regional association plots of the three-stage GWA meta-analysis is given in 
Supplementary Materials and Methods. At stage 1, seven GWA cohorts were included, and a 
suggestive significance threshold of α = 1.00×10−4 was applied for phosSNP selection. At 
stage 2 (in silico replication), three GWA cohorts were included, and at stage 3 (de novo 
genotyping replication), two independent cohorts were included, and at each stage, a 
Bonferroni-corrected significance threshold was applied.
PhosSNPs in Potential Phosphorylation Sites
The phosSNP-centric GWA meta-analysis focuses exclusively on 9,593 phosSNPs in stage 1 
of the conventional GWA meta-analysis.(31) Details about phosSNP selection are given in 
the Supplementary Materials and Methods.
In Silico Bioinformatics Analyses
(1) Computational Predictions of Phosphorylation Sites Affected by 
phosSNPs—Phosphorylation sites that could be affected by the three significant 
phosSNPs — IDUA rs3755955 (R105Q) and rs6831280 (A361T), and WNT16 rs2707466 
(WNT16B T263I), were predicted by two commonly used online software programs: 
NetPhos2.0(32) and NetPhosK1.0.(33) Details about these programs are given in the 
Supplementary Materials and Methods.
(2) Computational Predictions of Functional Impacts of phosSNPs—Functional 
effects of the three significant phosSNPs — IDUA rs3755955 (R105Q) and rs6831280 
(A361T), and WNT16 rs2707466 (WNT16B T263I) were computed using four online 
software tools: (i) Mutation Assessor,(34) (ii) BLOSUM62,(35) (iii) PMut,(36) and (iv) 
PANTHER.(37) Details about these tools are given in the Supplementary Materials and 
Methods.
(3) Computational Prediction of Protein Secondary and Tertiary Structures—
Protein secondary and tertiary structures were predicted by Protein Homology/analogy 
Recognition Engine Version 2.0 (Phyre2).(38,39) The Phyre2 server predicts a protein’s 
secondary structure based on the amino acid sequence. In brief, this program converts a 
protein sequence into a hidden Markov model (HMM) based on sequence homologs 
retrieved from experimentally determined known protein structures using PSI-Blast.(40) The 
HMM of the query sequence is then scanned against a non-redundant library of HMMs of 
proteins with experimentally determined structures. The 3D model of the query sequence is 
then constructed on the basis of alignments between the HMM of query sequence and the 
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HMMs of known structures. Phyre2 program can generate highly accurate models at low 
sequence identities (e.g., 15–25%).(39)
In Vitro Protein Expression Studies
To assess whether mutant (MUT) alleles of respective phosSNPs, i.e., IDUA rs3755955, 
rs6831280, and WNT16 rs2707466, could affect protein expression levels in vitro, we 
designed and constructed plasmid pcDNA3.1-Myc/His vectors harboring either wild-type 
(WT) or MUT allele of each phosSNP and transfected each of them into Chinese hamster 
ovary (CHO) cells. Details about cloning and transfection and Western blot analysis are 
given in the Supplementary Materials and Methods.
RESULTS
Cohort characteristics at three stages were presented in Supplementary Table S1. A detailed 
comparison of study designs of current study with those of two previous conventional GWA 
meta-analysis studies(31,41) is shown in Figure 1. In stage 1, current study restricted 
association tests to exclusively phosSNPs (~10K), as opposed to the entire set of genotyped 
and imputed SNPs (~5800K) of previous conventional study.(31) As a result, different SNP 
sets were selected from stage 1 for stage 2 in silico replication [9 phosSNPs for current 
study, and none overlapped with 33 SNPs of previous conventional study(31)]. In stage 2, 
different SNP selection criteria were employed between current study and previous 
conventional study.(31). Four stage 2-selected phosSNPs (i.e., IDUA rs3755955 and 
rs6831280, WNT16 rs2707466, and ESPL1 rs56358776) of current study were entirely 
different from those three stage 2-selected SNPs of previous conventional study(31) (i.e., 
SMOC1 rs227425, CLDN14 rs170183, and intergenic SNP rs6827815).
Stage 1 (GWA Discovery)
Table 1 presents a comparison of 33 SNPs selected in stage 1 of previous conventional 
study,(31) with those 9 phosSNPs selected in stage 1 of current study, which include four 
phosSNPs (located in three gene regions) attaining phosSNP-centric GWS (i.e., α = 
0.05/9,593 = 5.21×10−6) — IBSP rs1054627 for FN-BMD in female-specific sample, IDUA 
rs6831280 and rs3755955 for FN-BMD in gender-combined (i.e., male and female) sample, 
and WNT16 rs2707466 for HIP-BMD in gender-combined sample, and another five 
phosSNPs (located in four gene regions) attaining only suggestive significance (i.e., α = 
1.00×10−4) — SRMS rs310655 for FN-BMD in gender-combined sample, DNAH8 
rs61748601 for HIP-BMD in gender-combined sample, ESPL1 rs56358776 and rs1318648 
for LS-BMD in gender-combined and female-specific samples, respectively, and GPATCH1 
rs2287679 for FN-BMD in female-specific sample.
Stage 2 (in silico Replication)
In stage 2, the above 9 stage 1-discovered phosSNPs were subject to replication in three in 
silico independent cohorts. A meta-analysis within stage 2 revealed 6 phosSNPs at 
Bonferroni corrected α = 5.56×10−3 (i.e., 0.05/9): WNT16 rs2707466 for FN-BMD in 
gender-combined sample, IBSP rs1054627 for FN-BMD in gender-combined sample, 
ESPL1 rs1318648 and rs56358776 for LS-BMD in gender-combined sample, and IDUA 
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rs3755955 and rs6831280 for FN-BMD in gender-combined sample. Of these, IBSP 
encodes a well-known bone matrix protein that is important for bone mineralization(42–44) 
which, consequently, was not further tested in stage 3. For ESPL1 phosSNPs rs1318648 and 
rs56358776, neither reached GWS (i.e., 5.21×10−6 ≤ P-values < 1.00×10−4) in stage 1 
phosSNP-centric GWA meta-analysis. ESPL1 rs1318648 is a previously known nsSNP 
suggestively associated with FN- and LS-BMD phenotypes(41), whereas ESPL1 rs56358776 
is a novel nsSNP that was not reported in either of two previous conventional studies(41,45), 
which is in high linkage disequilibrium (LD) with ESPL1 rs1318648 [r2 = 0.798 in 1000 
Genomes (1KG) Pilot 1 CEU Population by applying the SNP Annotation and Proxy search 
(SNAP) tool(46) of Broad Institute]. Therefore, we selected 4 stage 2-replicated phosSNPs 
— IDUA rs6831280 and rs3755955, WNT16 rs2707466, and potentially novel phosSNP 
ESPL1 rs56358776, for stage 3 de novo genotyping replication.
Stage 3 (de novo Genotyping Replication)
In stage 3, the above four stage 2-selected phosSNPs identified were subject to further 
replication by de novo genotyping. Three of these phosSNPs were replicated by stage 3-
specific meta-analysis at Bonferroni corrected α = 0.0125 (i.e., 0.05/4). WNT16 rs2707466 
was consistently replicated for HIP-, FN-, and LS-BMD phenotypes in gender-combined 
sample. IDUA rs3755955 and rs6831280 were significantly associated with FN- and HIP-
BMD phenotypes in gender-combined sample. ESPL1 rs56358776 was not replicated at this 
stage (P-value = 0.79, 0.78, and 0.32 in gender-combined sample for FN-, HIP-, and LS-
BMD, respectively).
Stage 1+2+3 Meta-analysis
Table 2 presents ethnicity-specific and combined meta-analysis results aggregating these 3 
stages for stage 1-discovered (α = 1.00×10−4), and stage 2- and 3-replicated (Bonferroni-
corrected α = 5.56×10−3 and 0.0125, respectively) phosSNPs — IDUA rs6831280 (A361T), 
IDUA rs3755955 (R105Q), and WNT16 rs2707466 (WNT16B T263I), respectively. In 
ethnicity-specific meta-analyses, in Caucasians, all three attained phosSNP-centric GWS 
(i.e., α = 5.21×10−6) for FN-BMD and only WNT16 rs2707466 attained this threshold for 
HIP-BMD and in Asians, only WNT16 rs2707466 attained phosSNP-centric GWS for HIP-
BMD. The effects of these phosSNPs were consistent between Caucasian and Asian 
ethnicities. In combined meta-analysis across 3 stages, IDUA rs3755955 was significantly 
associated with FN- and HIP-BMD phenotypes (P-value = 8.36×10−10 and 3.26×10−6, 
respectively). Likewise, IDUA rs6831280 was significantly associated with FN- and HIP-
BMD phenotypes (P-value = 5.26×10−10 and 1.97×10−6, respectively). Similarly, WNT16 
rs2707466 was significantly associated with FN- and HIP-BMD phenotypes (P-value = 
3.01×10−10 and 1.63×10−12, respectively). Regional association plots were generated for 
these three significant phosSNPs — IDUA rs3755955 and rs6831280 (Figure 2), and 
WNT16 rs2707466 (Figure 3).
Phosphorylation Sites Predicted to be Affected by IDUA and WNT16 PhosSNPs
Based on predictions by NetPhos2.0 and NetPhosK1.0, four phosphorylation sites (have 
either a NetPhos2.0 score > 0.5 or a NetPhosK1.0 score > 0.5) were predicted by these two 
in silico bioinformatics tools that could be affected by these three BMD-associated 
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phosSNPs (Table 3). Detailed information on 96 and 54 predicted phosphorylation sites for 
IDUA and WNT16B were presented in Supplementary Tables S2 and S3, respectively. 
IDUA phosphorylation sites T98 and S102 were potentially affected by their neighboring 
phoSNP IDUA rs3755955 (R105Q), whereas IDUA phosphorylation site T366 was 
potentially affected by a neighboring phoSNP IDUA rs6831280 (A361T). WNT16B 
phosphorylation site T263 was potentially directly abolished by phoSNP WNT16 rs2707466 
(WNT16B T263I). Of them, WNT16B T263 (affected by WNT16 rs2707466) has been 
experimentally validated to be phosphorylated in vivo,(47) whereas IDUA T98 and S102 
(potentially affected by IDUA rs3755955) and T366 (potentially affected by IDUA 
rs6831280) have yet not been experimentally confirmed.
Predicted Functional Impacts of IDUA and WNT16 PhosSNPs
As shown in Supplementary Table S4, although IDUA rs6831280 (A361T) and rs3755955 
(R105Q) were predicted to have no (Mutation Assessor and BLOSUM62 scores) or low 
(PMut and PANTHER scores) functional impacts, WNT16 rs2707466 (WNT16B T263I) 
showed highest Mutation Assessor score (0.705; nearly reaching a “low impact” threshold 
0.80), lowest BLOSUM62 score of (−1.00; indicative of “evolutionarily less acceptable”), 
highest PMut pathogenicity score (0.3099; indicative of a “moderate pathogenicity”), and 
lowest PANTHER subSPEC score (−1.92476; indicative of a deleterious effect 
corresponding to a highest deleteriousness probability Pdeleterious = 0.25441). Further, 
evolutionary analysis by multiple sequence alignment method revealed that a 27-amino-acid 
peptide (−14 — +12) surrounding the T263 phosphorylation site is conserved across three 
mammalian species — human, mouse and rat (Supplementary Figure S1), supporting a 
likely functional significance of this phosSNP. Based on these bioinformatics prediction 
results, we further assessed the potential impact of WNT16 rs2707466 (WNT16B T263I) on 
WNT16B secondary and tertiary structures.
Predicted Secondary and Tertiary Structures of WT and MUT alleles for WNT16 PhosSNP
The secondary and tertiary structures of protein isoforms encoded by WT and MUT alleles 
for WNT16 rs2707466 (WNT16B T263I) predicted by Phyre2 server are presented in 
Supplementary Figures S2 and S3, respectively. With respect to secondary structures, this 
phosSNP (i.e., T263 residue) is located in a disordered region (indicated by a tract of “?” 
symbols) typical for a phosphorylation site,(48) downstream of a predicted β-strand 
(SIQISDK) for either isoform (Supplementary Figure S2) with potential functional effects 
(Supplementary Table S4). A comparison of the local 3D structures between WT and MUT 
isoforms near the T263 residue clearly shows different spatial patterns (Supplementary 
Figure S3, dashed boxes).
Effects of IDUA and WNT16 PhosSNPs on Protein Stability
In CHO cells, Western blot results showed that, at the protein level, IDUA rs6831280 
(A361T) and rs3755955 (R105Q) MUT alleles were expressed at equivalent levels compared 
with the IDUA WT allele (Panel As for Supplementary Figures S4 and S5, respectively). 
The WNT rs2707466 (WNT16B T263I) MUT allele was also expressed at equivalent levels 
compared with the WNT16 WT allele (Panel B for Supplementary Figures S4 and S5, 
respectively). Overall, the protein expression of the MUT allele is equivalent to that of the 
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WT allele for each of these three phosSNPs, suggesting that their influences of protein 
phosphorylations could be important, rather than on expression levels per se.
DISCUSSION
In human genome, nsSNPs account for 60% of mutations that cause diseases.(12) However, 
not all nsSNPs lead to a functional impact. Therefore, it is essential to select only those 
nsSNPs that are most plausible causal variants. Our study is unique in associating phosSNPs 
affecting the most common type of PTM with BMD phenotypes by taking a three-stage 
approach to protect against an inflated false positive rate. Beyond detecting genetic 
association, we also performed in silico and in vitro functional characterizations of identified 
significant nsSNPs. At stage 1, four chromosomal loci i.e., 4p16.3 (IBSP), 4q22.1 (IDUA), 
7q31.31 (WNT16), and 20q13.33 (GPATCH1), were detected by both the current and 
conventional studies,(31) but were represented by totally different SNPs, and for 4q22.1 and 
20q13.33, represented by different genes. At 7q31.31, the previous study detected 
association with intergenic SNP rs10242100 (with no apparent functional significance) near 
WNT16 gene, which is in moderate LD with the WNT16 SNP rs2707466 detected by our 
current study [r2 = 0.462 in 1KG Pilot 1 CEU Population by applying SNAP tool(46)]. 
Overall, three phosSNPs (IDUA rs6831280 and rs3755955, and WNT16 rs2707466), were 
discovered in stage 1 and were independently replicated in stages 2 and 3, respectively. In 
ethnicity-specific meta-analyses, their effects were consistent in subgroups of Caucasian and 
Asian ancestries, and statistical significances were greater in Caucasian than in Asian 
samples in part because of a larger Caucasian sample size (Table 2). In combined stage 
1+2+3 meta-analysis, all three phosSNPs reached conventional GWS for FN-BMD, and 
WNT16 rs2707466 attained conventional GWS for HIP-BMD also. By applying NetPhos2.0 
and NetPhosK1.0, 96 and 54 predicted phosphorylation sites in IDUA and WNT16B 
proteins, respectively (Supplementary Tables S3 and S4). IDUA encodes a glycosyl 
hydrolase that hydrolyzes the terminal alpha-L-iduronic acid residues of two 
glycosaminoglycans, dermatan sulfate and heparan sulfate(49). Wang et al. (2010)(50) created 
Idua-W392X mouse model, and found that 35-week-old homozygous Idua-W392X mice 
showed a 24% increase in femur BMD, and bone abnormalities such as thickening of the 
zygomatic arch and aberrations in the length and width of the femur were also observed(50).
For IDUA protein, a predicted phosphorylation site T366 could be indirectly affected by 
IDUA rs6831280 (A361T), a Type III phosSNP, and two predicted phosphorylation sites 
T98 and S102, could be indirectly affected by IDUA rs3755955 (R105Q), a Type II(+) 
phosSNP (Table 3). For WNT16B protein, phosphorylation site T263 could be directly 
abolished by WNT16 rs2707466 (WNT16B T263I), a Type I(−) phosSNP. Of them, only 
WNT16B T263 has been experimentally validated to be a genuine phosphorylation site by 
mass spectrometry technology in a phosphoproteomic analysis of human embryonic stem 
cells in vivo.(47) Whether IDUA T98 and S102, and T366 are actual phosphorylation sites 
influenced by nearby IDUA phosSNPs rs3755955 (R105Q) and rs6831280 (A361T) remain 
to be experimentally determined.
WNT16 encodes a member of the wingless-type MMTV integration site family, which has 
been reported to mediate signaling via both canonical and non-canonical Wnt pathways. 
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Wnt proteins are known to play important roles in vertebrate skeletal development.(51–53) 
Wnt16 is expressed in osteoid tissue of craniofacial bones during embryonic development in 
mice, and suppresses osteoblast differentiation through the canonical β-catenin pathway in 
MC3T3-E1 preosteoblasts.(54) Several GWA meta-analysis studies have demonstrated that 
WNT16 intron 3 SNP rs3801387,(41) exon 2 rs2908004 (WNT16B G82R) and exon 4 
rs2707466 (WNT16B T263I)(55,56) as well as intergenic SNP rs10242100(31) are associated 
with BMD phenotypes (Figure 3). However, functional roles of non-coding SNPs 
rs10242100 and rs3801387, which are in almost perfect LD [r2 = 0.915 in 1KG Pilot 1 CEU 
Population by applying SNAP tool(46)], remain unclear. WNT16 exon 2 rs2908004 
(WNT16B G82R) and exon 4 rs2707466 (WNT16B T263I) are shown to be in nearly 
complete LD [r2 = 0.933 in 1KG Pilot 1 CEU Population by applying SNAP tool(46)], which 
could represent the same phosphorylation association signal (i.e., WNT16 rs2707466). 
Consistent with our results, exon 2 nsSNP rs2908004 was significantly associated with 
upper limbs BMD, lower limbs BMD, as well as skull BMD phenotypes, and is the top 
signal in the chromosome 7q31.31 region in a GWA meta-analysis of the Avon Longitudinal 
Study of Parents and their Children and Generation R Study.(57) The phosSNP WNT16 
rs2707466 results in a substitution of threonine by isoleucine in both WNT16A (amino acid 
position 253) and WNT16B (amino acid position 263) isoforms. This phosSNP is predicted 
to exert a modest impact on protein function (by Mutation Assessor), and to be 
evolutionarily less acceptable (by BLOSUM62) and moderately deleterious (by PMut and 
PANTHER) (Supplementary Table S4). Because WNT16B T263 has been experimentally 
confirmed to be a phosphorylation site in vivo,(47) in silico secondary structure prediction 
shows that T263 is located in a disordered region (Supplementary Figure S2). This is in 
agreement with findings of Dephoure et al.,(58) which demonstrated that phosphorylation 
sites mostly occur in disordered regions, and the addition of a phosphate group to acceptor 
residue upon phosphorylation can lead to a disorder-to-order transition.(59) Predicted local 
3D structures also indicate notable differences between WT and MUT isoforms around T263 
phosphorylation site (Supplementary Figure S3). Taken together, it is highly probable that 
T263, a phosphorylatable residue located in a disordered region of WNT16B protein, acts as 
a switch for regulating protein-protein interactions,(59) and WNT16 rs2707466, a type I(−) 
phosSNP that abolishes this phosphorylation site, constitutes a causal variant for BMD 
phenotype. This is supported by observations of wnt16 null mice, which had significantly 
reduced total body BMD, thinner cortical bones at the femur midshaft, and reduced bone 
strength of both the femur and tibia.(55,56). Further, local injection of WNT16B (WT form) 
could increase BMD, providing direct experimental evidence that WNT16 gene is critical for 
skeletal development.(25)
There are several limitations of our study. First, 9,593 phosSNPs included in stage 1 (GWA 
discovery) of current study represent 14.98% of the entire 64,035 phosSNP set. 
Nevertheless, the original 5,842,825 autosomal SNPs either directly-typed or imputed in 
stage 1 of conventional GWA study(31) only covered 15.92% of entire 36.7 million human 
autosomal SNP set(60). Therefore, although these included phosSNPs appear limiting, they 
constitute a similar proportion of total phosSNPs as the original stage 1 SNP set of previous 
conventional study(31). Second, our in vitro protein expression experiments of WT and MUT 
alleles of IDUA rs3755955 (R105Q), rs6831280 (A361T), and WNT16 rs2707466 
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(WNT16B T263I) only demonstrated relatively equivalent protein expression levels between 
WT and MUT alleles (Panel Bs of Supplementary Figures S4 and S5, respectively). 
Additional experiments by applying phospho-specific antibodies could be insightful to 
reveal whether these phosSNPs truly affect protein phosphorylations either directly (for 
WNT16 phosSNP rs2707466) or indirectly (for IDUA phosSNP rs6831280 and rs3755955). 
However, such experiments are time-consuming and the extents of such differences may be 
challenging to detect, because both IDUA and WNT16B proteins can have multiple 
phosphorylation sites, and these phosSNPs may only affect 1–2 among them. It also remains 
to be shown whether a fraction of BMD variation is attributed to impacts of IDUA 
rs6831280 (A361T) and rs3755955 (R105Q) on their neighboring IDUA putative 
phosphorylation sites T98, S102 and T366, and to abolishment of WNT16B T263 
phosphorylation site by WNT16 rs2707466 (WNT16B T263I). Nevertheless, the study of 
Moverare-Skrtic et al.(25) clearly demonstrated a pivotal role of WNT16B WT isoform in 
skeletal development, and phosSNP rs2707466 could indeed play a major functional role in 
regulating bone metabolism.
The collective findings from our multi-stage phosSNP-centric GWA meta-analysis identified 
and robustly validated three phosSNPs, IDUA rs6831280 and rs3755955 and WNT16 
rs2707466, to be significantly associated with FN- and HIP-BMD. These results could offer 
new mechanistic insights of causal variants for osteoporosis. Because currently there is a 
lack of bone-specific phosphorylation maps, for those phosphorylation sites that are 
impacted by these BMD-associated phosSNPs, more studies are necessary to elucidate 
whether phosphorylations affected by them are present in these various types of bone cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. 
Diagrammatic representations of study designs of three-stage GWA meta-analysis of current 
study (top panel), Zhang et al. (2014)(31) (middle panel), and Estrada et al. (2012)(41) 
(bottom panel)
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FIGURE 2. 
Regional association plots for chromosome 4p16.3 loci IDUA Exon 3 phosSNP rs3755955 
(R105Q), Exon 8 phosSNP rs6831280 (A361T), intergenic SNP rs6827815, and FGFRL1 
3’-untranslated region SNP rs4647940 based on RefSeq accession number NG_008103.1 for 
FN-BMD (most significant phenotype). (A) IDUA rs6831280 with flanking ± 100-kb (B) a 
zoomed-in view of the center region [indicated by the dashed box of (A)] — IDUA 
rs6831280 with flanking ± 40-kb. PhosSNPs were highlighted in bond font
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FIGURE 3. 
Regional association plot for WNT16 rs2707466 with flanking ± 100-kb for HIP-BMD 
(most significant phenotype), with chromosome 7q31.31 WNT16 Exon 2 nsSNP rs2908004 
(WNT16B, G82R), Intron 3 SNP rs3801387, Exon 4 phosSNP rs2707466 (WNT16B 
T263I), and intergenic SNP rs10242100 based on RefSeq accession number NG_029242.1 
indicated. The phosSNP was highlighted in bond font
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